PIB TrackerThe ban on advertising prescription drugs would extend from makers to chemists
A draft amendment to the Drugs Rules, 1945 would require central sanction before any retailer or wholesaler advertises a Schedule H, H1 or X medicine.
What happened
- The Health Ministry proposed amending the Drugs Rules, 1945 to extend the advertising restriction on Schedule H, H1 and X drugs to sale and distribution licence holders.
- The instrument is insertion of sub-rule (22) under Rule 65, covering holders of licences to sell, stock, exhibit or offer for sale, or distribute drugs.
- Manufacturers are already barred from advertising these drugs without prior sanction of the Central Government; retailers and wholesalers were not explicitly covered.
- Notified as draft via Gazette Notification G.S.R. 861(E) dated 28 September 2026, after consultation with the Drugs Technical Advisory Board.
- It follows the 93rd DTAB meeting of 16 February 2026; objections invited within 30 days.
For Prelims
- Drugs Rules, 1945: framed under the Drugs and Cosmetics Act, 1940, they contain the schedules that classify medicines by the control applied to their sale.
- Schedule H: prescription-only drugs. Schedule H1: a subset including third and fourth generation antibiotics, anti-TB drugs and some habit-forming medicines, for which the chemist must keep a separate register recording prescriber, patient, drug and quantity, retained for three years.
- Schedule X: narcotic and psychotropic substances, requiring a special licence, a prescription in duplicate retained by the chemist, and separate storage.
- Drugs Technical Advisory Board: the statutory expert body under section 5 of the 1940 Act that advises the Centre and States on technical matters; rule changes of this kind normally originate in its recommendations.
- The companion statute: the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, which prohibits advertising remedies claiming to cure specified diseases - a different and older control from the schedule-based one here.
- Antimicrobial resistance: the reason antibiotic promotion is treated as a public health risk rather than a commercial matter. India’s National Action Plan on AMR identifies over-the-counter antibiotic sale as a principal driver.
- Pre-legislative consultation: a draft rule is published by gazette notification with a fixed objection period before finalisation - the standard route for subordinate legislation, and the point at which industry comment formally enters.
- Why sellers were the gap: online pharmacies and chain retailers advertise medicines directly to consumers in a way a single chemist never could, so a rule written for manufacturers no longer covers the channel that reaches patients.
For UPSC: A compact example of subordinate legislation closing a regulatory gap, with the statute, the schedules, the expert body and the consultation route all named. Deploy it on drug regulation and public health, on antimicrobial resistance and self-medication, on how rules are made under a parent Act, and on regulating a supply chain rather than a single actor.
What it is NOT: No data on the problem being solved: no count of unauthorised advertisements detected, no enforcement action taken under the existing manufacturer prohibition, and no evidence that retailer advertising is driving self-medication. Nothing on online pharmacies, which is the channel where consumer-facing drug promotion actually happens and whose regulatory status remains unsettled. No penalty is specified for breach of the new sub-rule. And nothing on enforcement capacity - State drug controllers already struggle to inspect retail premises, and monitoring advertising is a different skill again.
For Mains
Syllabus: GS2.10 · GS2.9 · Linkage L1
Anchor
The Health Ministry has notified a draft amendment to the Drugs Rules, 1945 that would require prior sanction of the Central Government before any holder of a licence to sell, stock, exhibit or distribute drugs advertises a medicine listed in Schedule H, H1 or X. Manufacturers already face that restriction; retailers, wholesalers and distributors did not.
Substantiation (data)
The instrument is a new sub-rule (22) under Rule 65, notified as a draft through gazette notification G.S.R. 861(E) of 28 September 2026 after consultation with the Drugs Technical Advisory Board, whose 93rd meeting in February considered the need for provisions governing advertisements by sale and distribution licence holders. Objections are invited within thirty days. The stated purpose is to discourage unauthorised promotion and reduce inappropriate self-medication, particularly of antibiotics and psychotropic medicines.
Position
Regulating the chain rather than the maker is the right correction, and it is overdue for a structural reason. A rule written in 1945 assumed the manufacturer was the only party with the means to advertise. Online pharmacies and retail chains now market directly to consumers at a scale no individual chemist could, and they are sellers, not makers - so the prohibition simply did not reach the channel through which prescription-drug promotion now actually arrives at a patient.
Counterpoint
The release offers no evidence of the problem. There is no count of unauthorised advertisements, no enforcement data under the existing manufacturer prohibition, and no study linking retailer promotion to self-medication - so the size of the gap being closed is unstated. More significantly, online pharmacies are never mentioned, although they are the obvious target, and their own regulatory status under the Drugs and Cosmetics framework has been unsettled for years. A rule that depends on identifying who holds a sale licence may not reach a platform that argues it holds none.
Way forward
Two things would give this force. A stated penalty, since the draft creates an obligation without naming a consequence; and an explicit application to online pharmacies and marketplaces, which would settle a question the sector has avoided. Enforcement is the harder half - State drug controllers inspect premises, and detecting an advertisement requires monitoring media and platforms, which is a capability the drug regulatory system does not currently have.
Conclusion
A sensible closing of a gap that opened because the market changed and the rule did not. Whether it matters depends entirely on whether it reaches the online channel, which the draft neither mentions nor excludes.
Deploys into: Drug regulation and public health · Antimicrobial resistance and self-medication · Subordinate legislation and pre-legislative consultation · Regulating supply chains rather than single actors
Ministry of Health and Family Welfare · 2026-10-09 · PRID 2321172 · PIB source ↗